286 related articles for article (PubMed ID: 27401561)
1. Interaction of Avibactam with Class B Metallo-β-Lactamases.
Abboud MI; Damblon C; Brem J; Smargiasso N; Mercuri P; Gilbert B; Rydzik AM; Claridge TD; Schofield CJ; Frère JM
Antimicrob Agents Chemother; 2016 Oct; 60(10):5655-62. PubMed ID: 27401561
[TBL] [Abstract][Full Text] [Related]
2. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
[TBL] [Abstract][Full Text] [Related]
3. Cyclic Boronates Inhibit All Classes of β-Lactamases.
Cahill ST; Cain R; Wang DY; Lohans CT; Wareham DW; Oswin HP; Mohammed J; Spencer J; Fishwick CW; McDonough MA; Schofield CJ; Brem J
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115348
[TBL] [Abstract][Full Text] [Related]
4. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
Lahiri SD; Bradford PA; Nichols WW; Alm RA
J Antimicrob Chemother; 2016 Oct; 71(10):2848-55. PubMed ID: 27402011
[TBL] [Abstract][Full Text] [Related]
5. Avibactam and inhibitor-resistant SHV β-lactamases.
Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
[TBL] [Abstract][Full Text] [Related]
6. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition.
Brem J; van Berkel SS; Aik W; Rydzik AM; Avison MB; Pettinati I; Umland KD; Kawamura A; Spencer J; Claridge TD; McDonough MA; Schofield CJ
Nat Chem; 2014 Dec; 6(12):1084-90. PubMed ID: 25411887
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
8. Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization.
Farhat N; Gupta D; Ali A; Kumar Y; Akhtar F; Kulanthaivel S; Mishra P; Khan F; Khan AU
Microbiol Spectr; 2022 Oct; 10(5):e0045022. PubMed ID: 36069578
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in β-lactamase inhibitor chemotypes and inhibition modes.
Li R; Chen X; Zhou C; Dai QQ; Yang L
Eur J Med Chem; 2022 Nov; 242():114677. PubMed ID: 35988449
[TBL] [Abstract][Full Text] [Related]
10. The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam.
Wang DY; Abboud MI; Markoulides MS; Brem J; Schofield CJ
Future Med Chem; 2016 Jun; 8(10):1063-84. PubMed ID: 27327972
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
[TBL] [Abstract][Full Text] [Related]
12. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.
Lahiri SD; Johnstone MR; Ross PL; McLaughlin RE; Olivier NB; Alm RA
Antimicrob Agents Chemother; 2014 Oct; 58(10):5704-13. PubMed ID: 25022578
[TBL] [Abstract][Full Text] [Related]
13. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
14. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Lee M; Abbey T; Biagi M; Wenzler E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
[TBL] [Abstract][Full Text] [Related]
15. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D
Compain F; Arthur M
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461318
[TBL] [Abstract][Full Text] [Related]
16. Metallo-β-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery.
Yang Y; Yan YH; Schofield CJ; McNally A; Zong Z; Li GB
Trends Microbiol; 2023 Jul; 31(7):735-748. PubMed ID: 36858862
[TBL] [Abstract][Full Text] [Related]
17. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases.
Lahiri SD; Mangani S; Durand-Reville T; Benvenuti M; De Luca F; Sanyal G; Docquier JD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2496-505. PubMed ID: 23439634
[TBL] [Abstract][Full Text] [Related]
18. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
19. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
